Treatment of hepatorenal syndrome.
Five patients with hepatorenal syndrome were treated with a LeVeen peritoneovenous shunt and furosemide. Four of the five patients responded immediately with urinary volumes in excess of 2 liters on the day of surgery and the subsequent 3 postoperative days. Urinary sodium excretion increased from 5 to 122 mEq/liter after insertion of a peritoneovenous shunt. Body weight decreased by 7.7 kg in 1 week. Serum creatinine decreased from 4.0 to 1.8 mg/dl in 1 week. There were two long-term survivors. Peritoneovenous shunting is an effective method of reversing the renal component in the hepatorenal syndrome.
D000328:Adult; D001201:Ascites / Q000628:therapy; D001202:Ascitic Fluid; D003401:Creatine / Q000097:blood; D005665:Furosemide / Q000627:therapeutic use*; D006801:Humans; D007263:Infusions, Parenteral; D007674:Kidney Diseases / Q000150:complications / Q000601:surgery / Q000628:therapy*; D007676:Kidney Failure, Chronic / Q000150:complications / Q000188:drug therapy; D008103:Liver Cirrhosis / Q000628:therapy; D008107:Liver Diseases / Q000150:complications / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D008875:Middle Aged; D009318:Natriuresis; D013577:Syndrome; D014683:Vena Cava, Superior / Q000601:surgery
D005665:Furosemide; D003401:Creatine